Among 206 people visiting a county HIV clinic between 2006 and 2013, there was an overall 17.5% prevalence of transmitted drug resistance.
Researchers investigating the prevalence of HIV transmitted drug resistance (TDR) have found a high prevalence of TDR among newly diagnosed, treatment-naïve individuals seeking care at a county HIV clinic in Santa Clara County, California.
Notably, the study included integrase strand transfer inhibitors (INSTIs) in the classes of drugs for which TDR was assessed. To date, there have been few studies researching TDR to INSTIs among people living with HIV, and the available data have indicated that there is a low prevalence or an absence of this occurrence.
Identifying the prevalence of INSTI TDR has important implications, as “INSTI resistance mutations are not routinely included in standard baseline resistance testing, but they are expected to increase in the future as INSTIs are currently a recommended antiretroviral therapy (ART) by the US Department of Health and Human Services,” wrote the researchers.
Among 206 people visiting the clinic between 2006 and 2013, there was an overall 17.5% prevalence of TDR. Among 4 commonly used antiretroviral drug classes, the prevalence of TDR to nonnucleoside reverse transcriptase inhibitors was 7.3%, followed by 6.8% for nucleoside reverse transcriptase inhibitors, 2.9% for INSTIs, and 2.4% for protease inhibitors.
There was a nearly 2% prevalence of dual-class resistance among those with TDR, and there were no patients with triple- or quadruple-class resistance.
For those with INSTI resistance, the only mutation associated with resistance was E138A.
“Although there is no indication of a significant, underlying trend, it should be noted that instances of E138A doubled in 2010-2013 compared to 2007-2009, which could be a result of increasing INSTI usage,” wrote the researchers. “Given our finding of a mutation associated with INSTI resistance, testing for INSTI resistance during routine genotyping should be considered.”
With HIV TDR occurring from the transmission of drug-resistant infection from one individual to another, the researchers added that the findings can help improve ART outcomes and prevent future transmission events.
They did note that their study sample is not a comprehensive representation of the general population, so the results may not fully reflect the county’s TDR patterns.
Reference
Chan W, Ly W. Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County. Heliyon. 2019;5(9):e02411. doi: 10.1016/j.heliyon.2019.e02411.
Elevating Equitable Health Care for the LGBTQ+ Community
June 18th 2024For the third episode in our special Pride Month series, we speak with Patrick McGovern, CEO of Callen-Lorde since August of 2023 and an outspoken advocate for HIV; lesbian, gay, bisexual, transgender, queer, plus (LGBTQ+); and community health.
Listen
Community Outreach Is Enabling CeSHHAR to Close HIV Care Gaps in Zimbabwe
April 6th 2021The Centre for Sexual Health and HIV/AIDS Research Zimbabwe conducts evidence-based research related to HIV and AIDS, as well as provides and implements sexual and reproductive health education and interventions among sex workers, children, and adolescents, and in the area of masculinity.
Listen
Empowering Young Women in the Fight Against HIV
November 8th 2024As part of our coverage of the biennial AIDS conference from the International AIDS Society, we spoke with Madalitso Juwayeyi, program manager at FACT-Malawi, to learn more about her organization and how it strives to serve the sexual and reproductive health needs of adolescent girls and young women in her native Malawi.
Read More